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Abstract
Patients with Type I Diabetes (T1D) must take insulin injections to prevent the serious
long term effects of hyperglycemia – high blood glucose (BG). These patients must also
be careful not to inject too much insulin because this could induce hypoglycemia (low
BG), which can potentially be fatal. Patients therefore follow a “regimen” that, based
on various measures, determines how much insulin to inject at certain times. Current
methods for managing this disease require adjusting the patient’s regimen over time
based on the disease’s behavior (recorded in the patient’s diabetes diary).
If we can accurately predict a patient’s future BG values from his/her current
features (e.g., predicting today’s lunch BG value given today’s diabetes diary entry for
breakfast, including insulin injections, and perhaps earlier entries), then it is relatively
easy to produce an effective regimen. This study explores the challenges of BG
modeling by applying a number of machine learning algorithms, as well as various data
preprocessing variations (corresponding to 312 [learner, preprocessed-dataset]
combinations), to a new T1D dataset that contains 29 601 entries from 47 different
patients. Our most accurate predictor is a weighted ensemble of two Gaussian Process
Regression models, which achieved an errL1 loss of 2.70 mmol/L (48.65 mg/dl). This
was an unexpectedly poor result given that one can obtain an errL1 of 2.91 mmol/L
(52.43 mg/dl) using the naive approach of simply predicting the patient’s average BG.
For each of data variant and model combination we report several evaluation metrics,
including glucose-specific metrics, and find similarly disappointing results – again, the
best model was only incrementally better than the simplest measure. These results
suggest that the diabetes diary data that is typically collected may not be sufficient to
produce accurate BG prediction models; additional data may be necessary to build
accurate BG prediction models.
1 Introduction
Individuals suffering from Type I diabetes (T1D) are unable to produce insulin,
meaning their bodies cannot properly regulate their blood glucose (BG) [1] – i.e.,
cannot maintain their BG between 4 – 8 mmol/L [2]. As a result, T1D is a serious long
term condition that can lead to microvascular, macrovascular, neurolgical and metabolic
complications [1, 2].
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To manage their diabetes, patients give themselves periodic injections of insulin as
directed by their health care team. Injecting too much insulin may induce hypoglycemia
(BG< 4 mmol/L, in our study), which can be dangerous, possibly causing a coma.
However, injecting too little insulin can result in hyperglycemia (BG> 8 mmol/L, in
our study), which may lead to chronic complications such as blindness, kidney failure,
nerve damage and circulatory problems [1, 2]. In general, a patient’s BG will depend on
many factors, including past carbohydrate intake, the amount of bolus/basal insulin
injected, exercise, and stress [2].
Diabetes patients try to properly maintain their BG in a normal range. This is
challenging because tight glycemic control using bolus insulin injections (whether
intermittent with insulin pens or boluses using insulin pumps) is associated with an
increased the risk of having hypoglycemic events [1]. This challenge has led to attempts
to create closed-loop systems and the use of computational techniques that assist in
controlling patient’s BG levels [3]. An extreme example of this is the effort to create an
“artificial pancreas”, which explicitly integrates automatic monitoring with automatic
administration of insulin [4].
Another perspective on fully automated diabetes management views the BG control
problem as two sequential subproblems:
1. “modeling”: learning an accurate BG prediction model that, for example, predicts
the BG level at lunch given a description of the subject throughout breakfast
(including perhaps her previous BG values, carbohydrate intake, etc., from earlier
meals), as well as the amount of insulin injected at breakfast.
2. “controlling”: given the current information (at breakfast), consider the effects of
injecting various possible amounts of insulin – e.g., {1 unit, 1.5 units, 2 units, . . . }.
For each, use the learned model to predict the BG value at lunch, then inject the
amount that is predicted to lead to the best lunch time BG-value (Of course, this
assumes that decisions made at breakfast only affect lunch, then lunch decisions
will only affect dinner, etc. – which does not consider the longer-range effects of
actions; see Bastani [3]).
This paper focuses on the first subtask: developing a BG prediction system, where
in general, a model M will predict the blood glucose B̂Gi+1 = M(xi, ∆ti+1 ) at the
next time point (∆ti+1 minutes into the future), based on information currently known
about this patient, including the amount of insulin (bolusi) the patient decided to
inject (Note that this abstracts some issues; see Appendix A.1 for details):
xi = [timei, BGi, bolusi, basali, EVi, PVi, IOBi, . . . ] (1)
An example of this subtask might be to predict an individuals blood glucose at 12:01pm
lunch on Tuesday, given information collected up-until 8am breakfast on
Tuesday(Where this could only include the Tuesday breakfast information, or it could
include other earlier information – e.g., the ellipses in Equation 1 might contain
information about events from yesterday, or last week).
Explicitly, the goal of this work is to to determine if it is possible to accurately
predict a T1D patient’s recorded BG, from one meal to the next, based only on the
information typically recorded by the patient. To do this, a model must be able to deal
with the data provided in a patient’s diabetes diary, which has varied prediction
horizons.
This work is an extensive effort to learn an accurate BG prediction model, which
involved exploring 312 different combinations of learner and preprocessing variant. To
train and evaluate each of these variants, we used a dataset of 29 601 entries collected
from 47 unique patients, where each entry included the information typically collected,
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including: the time of day, the patient’s current BG, the carbohydrate about to be
consumed and the anticipated exercise.
1.1 Background Literature and its Limitations
As the mechanism of diabetes are not completely understood, we are considering the
machine learning approach of learning a model, from a large labeled dataset, containing
many records from many Type-1 diabetes patients. Of course, this requires access to
such a dataset. Previous studies have been based on data from small numbers of
subjects and/or data collected over a short time period. For example, several studies
have been based on data from a single patient where records were only collected for
fewer than 100 days [2, 5–7]. These studies are limited because different patients behave
very differently. Other studies include more patients (12 – 15) but only have 3 – 22 days
worth of data [8, 9]. Another study used three patients with two years of data [10].
Further, studies analyzing continuous glucose monitoring (CGM) data from larger
patient sets (89 T1D patients) exist but are again sampled over relatively short periods
of time (1 week) [11]. In these last four cases, datasets either had short histories for
their patients or they had a small number of patients in total. In contrast, our work
uses a larger number of patients who had up to two years worth of data, where records
were collected multiple times each day.
There are large datasets of type-2 diabetes patients – e.g., Quinn et al. [12]
measured glycated hemogloben changes in data collected data from 163 patients over
the course of a year. However, studies that model type-2 diabetes [13, 14] should not be
directly compared to those that model type-1 diabetes because there are significant
differences between these diabetes types. In particular, there is less variance in the
blood glucose readings over time for type-2 patients than there is for type-1 patients,
making type-2 patients easier to model.
While we focus on predicting BG values many hours later, some studies instead
attempt to predict the occurrence of hypoglycemic events, and only within a short
window (e.g., 30 to 120 minutes) [8, 15–18]. Indeed, a literature review by
Contreras et al. identified 49 publications using modeling techniques for blood glucose
prediction (primarily with T1D patients) of which 38 used predictions horizons that
were 60 minutes or less [19]. Of these, one of these publications included prediction
horizons of 180 minuets but on simulated data, and another had 1440 minute prediction
horizons but used a dataset of 8 patients collected over only 3 days [19]. While this
might help to protect patients from a very serious situation, it is lacking in several ways.
First, such fine-grained measurements are often not practically obtainable outside of a
study setting and without using a CGM device that provides measurements every 5
minutes. Second, these short-term predictions are not adequate for spanning the time
between meals. Third, the goal of building a diabetes control system is better served
with a more expressive model, as opposed to one that can only provide binary
classifications – hypoglycemic or not. Note that these model provides no useful feedback
for situations where patients are hyperglycemic.
In our work, we try to model blood glucose dynamics (including both hyperglycemia
and hypoglycemia) and using only the standard records collected at meal times. While
this makes our task more challenging, we do this because it involves only the data that
medical professionals most often encounter in practice.
Like Pappada et al. [20], we also considered neural network models. After training
on 17 T1D patients, Pappada et al.’s [20] evaluation, on a single held-out patient,
yielded “scores” (a version of the rL1 measure defined in Equation 5) of 0.067 (resp.,
0.089, 0.117, 0.145, 0.166, 0.189) when using predictive windows of 50 (resp., 75, 100,
120, 150 and 180) minutes in the future. While they were able to achieve a score of
0.189 using 180 minute predictive windows, note that their result is based on the test
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data of a single patient (other patients may be more difficult to predict) and that the
dataset used in their study involved relatively short-range predictions (50 – 180
minutes), while our study involves predictions made, on average, 310.6 minutes in the
future (averaging 593 minutes for overnight predictions and 236 minutes otherwise).
Since Pappada et al. showed that larger predictive windows decrease the accuracy of
their models, we expect that our data should be more difficult to model well. Also, their
study involved only 3 to 9 days of data with continuous glucose monitoring, whereas our
data were collected over a period of months to years.
Our work resembles previous works [21,22] that use Gaussian Process Regression
(GPR) for modeling diabetes. In particular, Duke [22] used GPR to learn models of
individual patients that could be used to aid in cross-patient prediction. We similarly
explore some transfer learning techniques with GPR, along with ensembles of learners
and various other machine learning algorithms.
Prior works have also addressed the blood glucose modeling problem that we explore
in this work [2, 6, 7]. These latter two evaluate their results using normalized blood
glucose values; since they are unitless normalized values, they cannot be directly
interpreted in terms of mmol/L, which means that we cannot compare our results to
theirs. However, we do evaluate the performance of a model that is similar to the
Gaussian Wavelet Neural Network used in the third [7].
One work of interest to our study is the previously mentioned 2018 publication by
Gadaleta et al. [11] that analyzes CGM data. In comparison to our work, this work
looks at shorter term blood glucose predictions over a shorter period of time but is
similar in that it provides a fairly comprehensive analysis of the predictive performance
of many different machine learning models. Gadaleta et al. focus on two different
methods for training and evaluating models, “static” and “dynamic”. Similarly to their
“dynamic” training process, the majority of our study focuses on training and testing on
data from each patient separately. However, the stacking models used in our work
effectively train a “static” model with a Leave One Patient Out and combine this model
with a patient-specific model. Gadaleta et al. consider combining “static” and
“dynamic” training processes as future work.
There are other works that define measures for evaluating the quality of glucose
predictors, in general. In particular, Del Favero et al. [23] describes several different
measures for comparing a patient’s specific glucose reading, with a predicted one,
including both standard measures (like L1, relative L1 error, and L2 losses – there
called MAD, MARD and RMSE) and some “glucose-specific metrics”, such as gMAD
and gRMSE [24]. While our paper focuses on the L1 and relative L1 errors, we also
include the others mentioned there.
1.2 Main Contributions
Below we list the main contributions of this work:
1. To our knowledge, this study examines the largest multi-year dataset of diabetes
diary records, collected from Type 1 diabetes patients, used for modeling future
BG.
2. We provide a comprehensive study of this data, considering 312 combinations of
learning algorithm and type of data, to determine if machine learning can be used
to create an accurate blood glucose prediction model.
3. Our results demonstrate that it is difficult for a machine learned model to perform
better than a naive baseline (in this case, predicting a patient’s average BG),
when considering both standard error measures, like L1 and L2 loss, and also for
glucose-specific measures, such as gMAD.
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Table 1. Summary of Demographics
Distinct Patients Age Height Weight Sex Pump Users
47 42± 13 166± 8 cm* 74± 14 kg 47 (9 ♂ / 38 ♀) 16
* Height could not be obtained for 7 individuals, so this average value was calculated using
only the remaining patients. See Borle [25] for more details about individual patients.
The publically available MSc thesis [25] that corresponds to this work provides
additional information, including a breakdown of the individual patients in the study,
more detailed results, and a comparison to a diabetologist’s performance on this
prediction task.
2 Materials and Methods
Section 2.1 first summarizes how we obtained this (real world) data; Section 2.2 then
describes the pre-processing steps required to make this data usable. We then consider
two ways to modify this dataset: Section 2.3 considers modifying the set of records; one
class of studies involves the complete set of entries, and another class included just the
subset of “Expert Predictable” records (defined below). For each of these two “sets of
record”, we consider various “feature sets” – the original set of features, and also 12
other variants, each of which includes various new features, that are combination of
those original features; see Section 2.4. Section 2.5 then summarizes the 12 different
learning algorithms we considered (based on 7 distinct base learners); and Section 2.6.1
describes a trivial baseline, to help us determine whether the results of any of the
learned models are actually meaningful. This requires describing how we evaluate the
quality of a learned model – see Section 2.6. (This segues naturally to Section 3, which
provides those empirical results.)
2.1 Dataset
This study used 47 patient histories from Type I diabetes patients, which were collected
using the “Intelligent Diabetes Management” (IDM) software(described in Ryan et
al. [26]). Note that the associated website https://idm.ualberta.ca/ has since been
decommissioned. This data included patients who participated in Ryan et al.’s study, as
well as additional patients who began using the IDM software after the completion of
the study (up until December 2016). The participants gave their informed written
consent, and the Research Ethics Board of the University of Alberta approved the
collection and analysis of the data. For further details regarding patient participation,
see Ryan et al. [26]. Some of the participants only used the system a few times. As we
wanted to focus on patients that had sufficient information to find relevant patterns, we
only included patients who made at least 100 diabetes diary entries with the system –
i.e., produced at least 100 “sufficient” records. This led to a dataset of 16 pump users
and 31 non-pump patients. Table 1 provides summary statistics for our data. The
dataset used for this work differs from the one described in Borle [25] in that we limit
the number of patients included to those with complete data.
Patient #16 is noteworthy for having by far the most records of any patient in our
dataset; it is unusual for a patient to consistently produce diabetes entries over the
course of many years. Because of the large number of records, we use part of this
patient’s dataset as our hyper-parameter tuning (validation) dataset, as well as for
visualization.
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Fig 1. Spline of Insulin on Board over Time.
Each record i corresponds to an entry in a patient’s “diabetes diary”, which includes
the meal associated with the record meali, a time stamp (datei and timei), the blood
glucose value BGi, the grams of carbohydrates consumed CHOi, and the units of bolus
(resp., basal) injected bolusi, (resp., basali). The patients also entered the anticipated
level of exercise using the non-numeric values {“less than normal”, “normal”, “active”,
“very active”}. We converted these into numeric values (2, 4, 7 and 10 respectively) for
use by standard learning algorithms.
As was mentioned, 16 of the patients in this study used insulin pumps, which each
directly infuse insulin from a reservoir, via a catheter, just under a patient’s skin at a
basal rate. Moreover, they also self-inject larger amounts of bolus insulin when a patient
ingests carbohydrates (as a patient would with an insulin pen
http://www.diabetes.org/living-with-diabetes/treatment-and-care/
medication/insulin/how-do-insulin-pumps-work.html). Each record of each
insulin pump patient includes the basal infusion rate value PVi, in
units
hour . The insulin
pump settings work by partitioning the 24h clock into intervals, and setting a particular
delivery rate of insulin for each interval. The PVi values for any specific record was
then set to the insulin delivery rate for the interval containing the record’s time stamp
We also computed two other features: ∆ti, which is the elapsed time since the previous
record (Actually, ∆ti is based on previous bolusi−1 and CHOi−1 values; see
Appendix A.1) and “Insulin on Board” IOBi, which captures the effect of any insulin
remaining in a person’s system from previous injections [27]. This was based on the
following pairs of elapsed time and percentage of post-injection insulin remaining [28]:
(1.66 hours, 78%), (2.5 hours, 48%), (3.33 hours, 27%), (4.15 hours, 12%), (5 hours, 3%).
We then used a simple spline to interpolate these values; see Fig 1. Table 2 formalizes
all of these features and Table 3 provides example data.
2.2 Data Preprocessing
The first step in analyzing the data was dealing with the missing or erroneous
(unreasonably low) values. We discarded any record that did not have an associated BG
value (572 records). This was necessary as we cannot evaluate a model on records where
we do not have a ground truth for BG. We also discarded any records that had missing
dates (6 records) because these timestamps are integral to deriving features from the
data. Second, we changed any BG value less than 1 mmol/L (8 records) to 1 mmol/L,
as glucose meters are simply not accurate at these low values, other than to state that
the values are very low. We then log-transformed these blood glucose values for all our
predictors, anticipating that this log-linear model would have better performance. This
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Table 2. Description of Original Features, and some Computed Features, used in this Study
meali The time of day: { Before Breakfast, After Breakfast, Before lunch, After Lunch,
Before Supper, After Supper, Before Bed, During the Night}
datei The date as year-month-day
timei The time as hour:minute:second
BGi The BG value at the current time (
mmol
L
)
CHOi The amount of carbohydrates ingested (grams)
bolusi The amount of insulin injected (units)
basali The units of background insulin injected
EVi Numeric encoding of exercise value: {2, 4, 7, 10}
PVi Pump Value: The rate at which the insulin pump is infusing (
units
hour
). This is always 0
if the patient does not have a pump.
∆ti The elapsed time since last record
IOBi Insulin on Board: Estimated residual insulin from the previous injection (
mmol
L
)
See text for further description of these terms. Note this is a simplified set of features; see Table 6 in the Appendix for the complete set
of feature descriptions.
Table 3. Example of Data, over a single day, from Patient 16
index i 27 28 29 30 31 32
meali Before Breakfast After Breakfast Before Lunch After Lunch Before Dinner After Dinner
datei 2015-11-25 2015-11-25 2015-11-25 2015-11-25 2015-11-25 2015-11-25
timei 08:36:00 10:19:00 12:19:00 15:35:00 18:42:00 20:11:00
BGi 16.2 14.7 5.6 6.8 10.5 3.0
CHOi 30.0 0 30.0 0 15.0 0
bolusi 10.4 0 3.0 0 3.8 0
basali 0 0 0 0 0 0
EVi 4 4 4 4 4 4
PVi 0.50 0.50 0.63 0.45 0.90 0.90
∆ti 540 103 120 196 187 89
IOBi 0.00 7.90 3.61 0.89 0.81 3.35
Note this is a simplified version of the data; Table 7 in the Appendix provides the general, complete set of features.
means that after this model makes a prediction, we must use simple exponentiation to
transform that prediction back into the original interpretable units.
To address missing bolus insulin and CHO carbohydrate values, we imputed
average values into the missing entry (variants for this step are described in Section 2.4).
This was done on a per-subject, per-meal basis – that is, we imputed an individual’s
average value for a particular meal. For example, say a specific patient injected, on
average, 3 units of bolus insulin before breakfast. Whenever she does not enter the
before-breakfast insulin, we replace that missing value with “3 units”. When dealing
with missing exercise values, we imputed the “normal” value. For missing basal insulin
values, we always imputed a constant value of 0. This allows a learner to distinguish
when basal insulin was recorded and when it was not. After this preprocessing, we
computed the auxiliary features (∆ti, IOBi) from the improved data. We describe the
complete set of features in Table 6, and we show example records as columns in Table 7;
see also Appendix A.1.
2.3 Subset of only “Expert Predictable” Entries
As our data was collected voluntarily from patients at their own convenience, sampling
intervals are not uniform, and the relevant data is not recorded for every meal. This is
problematic for our predictive task as blood glucose values are more difficult to predict
as more time elapses between readings. To address this issue, our clinician co-author
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Fig 2. Records Meeting the EP Criteria From Section 2.3. Patients are sorted
by descending total numbers of records. See Borle [25] for further details.
(E.A.R.) established the following criteria of when it is reasonable to predict the next
glucose value; the BG is “expert predictable” (EP) at a given time if all of the
following are true:
1. The preceding record is not a hypoglycemic event ( Note that this is difficult to
predict due to potential glucose counterregulation effects [29] and the uncertainty
in BG that follows from a physiological response to hypoglycemia).
2. The blood glucose reading is present for the preceding meal. For example, to
make a prediction about a patient’s blood glucose value before lunch, a record
detailing his/her previous breakfast must be available.
3. Six of the last eight days prior to a prediction must have records for both the
current meal time and the previous meal time. For example, to predict the blood
glucose before lunch, six of the last eight days must have both “before lunch” and
“after breakfast” entries, to help capture this “after breakfast to before lunch”
transition pattern.
Fig 2 shows the number of records from each patient that qualify as EP – the
number of records for which our expert would feel comfortable making predictions.
Later, we trained and evaluated 13 models using the entire dataset D (called { Da1,
Da2, . . . , Da13}) as well as 13 corresponding models that were trained and then
evaluated, using only the records that met the expert’s EP criteria, DEP (called { De1,
De2, . . . , De13 }). Note that the Da and De notation reflects that a dataset was
derived from either all the data points (Da) or from the expert’s subset D
EP (De).
2.4 Feature Engineering
Table 2 shows the basic features used to describe each event. Additionally, we also
considered many other feature sets to see if any could lead to better performance. Some
of the variants completed records that were missing entries for carbohydrates or bolus
insulin, which others removed those deficit records. Some added in the day of the week
as an integer feature or as a one-hot encoded feature (http://scikit-learn.org/
stable/modules/generated/sklearn.preprocessing.OneHotEncoder.html), while
others removed the “basal insulin” feature. A few variants included non-temporal
patient characteristics: age, gender, height and weight. Some replaced the set of
features with just the first 4 principal components (obtained by principal component
analysis, PCA).
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Our “Kok Features” variant uses computed features similar to Kok [2], and
subsequently used by Baghdadi et al. [6] and Zainuddin et al. [7]. Unlike Kok’s data,
however, we do not have stress level values in our data and were therefore unable to
incorporate that feature.
For any given dataset variant, some models have components that train on different
subsets of the data. In addition, we also use models that include components that are
trained on the data from all patients other than the current test patient, as well as
models that involve sub-models that are each trained only on data from one meal type
(e.g., before breakfast).
Note we consider each of these variants applied to the original dataset, and also to
the reduced “EP-filters” datasets; see Section 2.3. Note that this reduces the
predictions that our system attempts. For example, we do not attempt to predict a
before-lunch BG value if there is no preceding after-breakfast reading. For each variant,
we only considered the subset of the records that belonged to that variant, both for
producing the model and also for estimating the quality of that model – in particular,
the thirteen “EP”-models were trained and tested on the DEP set of records.
Table 8 (in Appendix A.1) describes all our dataset variants.
2.5 Machine Learning Algorithms
This work considers twelve different learners, based on seven base learning algorithms,
each run on each of the various different datasets (differing based on the feature
preprocessing used; see Section 2.4 K-Nearest Neighbors (KNN), Support Vector
Regression (SVR), Artificial Neural Networks (ANN), Wavelet Neural Networks (WNN),
Ridge Regression (RR), Random Forest Regression (RFR) and Gaussian Process
Regression (GPR). We used patient#16’s first 3260 diabetes diary entries from dataset
D21 to tune the hyper-parameters for the different base learners – e.g., for the GPR
model (nugget = 0.25), KNN model (K = 10, weighting = uniform), RF model
(maximum depth = 4), and our neural network model (batch size = 20, epochs = 1000).
These 3260 records were then excluded from our testing data to reduce the risk of
overfitting. All other unspecified parameters were defaults – e.g., the linear SVR model
(C = 1), SVR with RBF kernel model (C = 1, σ2 = 1
# of features
) and Ridge
regression model (α = 1) are the defaults provided by scikit-learn [30]. The ANN
architecture included one output neuron with linear activation and two hidden layers of
3× (# of features) with rectified linear activation. The WNN architecture included one
output neuron with linear activation and one hidden layer of (# of features) neurons
with Gaussian wavelet activations (Ψ(x) = −xe− 12x2). Most of these models were
implemented with the help of scikit-learn [30], except for the ANN that was
implemented using Keras [31] and the WNN that was implemented in part with
scikit-neuralnetwork
(http://scikit-neuralnetwork.readthedocs.io/en/latest/index.html). We
assume the reader is familiar with these fairly standard learners.
We also combined base learners to develop more complex learners. The following
section (Section 2.5.1) describes our GPR ensemble approach. We also considered
another approach, which incorporates the information from the other patients – e.g., use
patient histories #1 to #46 to help train a model for patient #47. This “Stacking”
approach first trains a model on the auxiliary patients, then runs this model on the test
patient’s data to produce a new feature for each meal – i.e., a 14th feature, to augment
the 13 features shown in Table 7. Appendix A.6 shows the entire stacking process.
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2.5.1 Modeling with a confidence weighted GPR Ensemble, Mwgpr
For each patient, our “GPR ensemble” model first creates two different GPR models,
then combines them into a single model called Mwgpr. The first of these two models,
GPRp, learns from the entirety of a patient’s training data. The second model,
{GRPm}, is actually a collection of GPR models – one for each possible meal category
m (corresponding to meali in Table 2. Each of these GPRm models is trained using
only the occurrences of that particular meal category in the patient’s training data (e.g.,
all occurrences of “Before Lunch”). Once we have obtained GPRp and the set of
GRPm models and wish to make a prediction for instance xi, we produce a weighted
prediction of the form
B̂Gi+1 =
1
α+ β
[α GPRp( [xi,∆ti+1] ) + β GPRm( [xi,∆ti+1] ) ] (2)
where α = 1σpi
and β = 1σmi , and where σpi and σmi are respectively the standard
deviations of the posterior Gaussian distributions N (GPRp( [xi,∆ti+1] ), σ2pi ) and
N (GPRm( [xi,∆ti+1] ), σ2mi ) at the point xi.
2.6 Model Evaluation
To assess the performance of our models in general, evaluation functions are required to
measure the quality of model predictions with respect to known true outcomes. In this
paper we report our results in terms of “L1-loss” (errL1), “relative L1-loss” (errrLl)
and Root Mean Squared Error (RMSE).
Given a model M(·) and a dataset
D = { [ [xi,∆ti+1], BGi+1 ] }i (3)
where each xi provides the “temporal information” shown in Equation 1, “L1-loss”
(errL1), “relative L1-loss” (errrLl), and RMSE are defined as
errL1(M(·), D ) = 1|D| − 1
|D|−1∑
i=1
| M(xi, ∆ti+1)−BGi+1 | (4)
errrL1(M(·), D ) = 1|D| − 1
|D|−1∑
i=1
| M(xi, ∆ti+1)−BGi+1 |
BGi+1
(5)
RMSE(M(·), D) =
√√√√ 1
|D| − 1
|D|−1∑
i=1
( M(xi, ∆ti+1)−BGi+1 )2 (6)
where BGi+1 is the blood glucose associated with the next time point, occurring ∆ti+1
minutes later (Note that Del Favero et al. [23] refers to errL1 and errrLl as MAD and
MARD, respectively).
For each of these three metrics we also consider “glucose-specific” variants. These
“glucose-specific” variants use a “Clark Error Grid inspired penalty function” to
re-weight the relative costs of different mispredictions (see Del Favero et al. [23] for
descriptions and definitions). Therefore in total, we consider the performance of our
models across 6 different evaluation functions (See Appendix A.3 for why we include
both errL1 and errrLl).
2.6.1 Baseline: Using a Naive Predictor
To establish a baseline for evaluating these learned models, we created a naive model
(Mavg) that, for each patient, simply predicted that patient’s average BG value (over all
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Fig 3. Illustration of 5-Fold CV with Contiguous Segments. In each CV
iteration training is done on the blue segments and testing on the green segment.
meals/records) based on his/her diabetes history – that is, the naive model predicted
the same average value (for that patient), independent of any other information about
that patient. More concretely, given a patient’s data D = {[. . . , BGi, . . . ]}i, partitioned
into a training set Dtrain and a test set Dtest, the model calculates the average blood
glucose for the entire training set
BGavg(D
train) =
1
|Dtrain|
∑
[...,BGi,... ]∈Dtrain
BGi (7)
including readings for all meals and all days. Then for all instances xj in the associated
test set Dtest, this model sets Mavg(xj , ∆tj+1 ) = BGavg(D
train). So, for patient 16:
as the BGavg value for her first training set was 8.4, this trivial model predicts that her
blood glucose value will be 8.4 for each meal in the associated test set. We can then
evaluate this trivial model using Equations 4, 5 and 6; we clearly hope that the
less-trivial models will do significantly better.
2.6.2 10-Fold Cross Validation
Each of our learners will take the entire dataset and produce a model. The next
challenge is evaluating this learned model. To evaluate the predictive quality of each
learner, we use 10-fold cross validation (CV), with respect to each patient. We first
partition time series history of a patient, denoted Xi, into ten contiguous segments
Xi =
⋃
j=1..10X
j
i . We then use nine of the ten segments for training in each CV round
and use the remaining one segment for testing – so the first split would be train
X1i,tr =
⋃
j=2..10X
j
i and test X
1
i,te = X
1
i . While the testing partition always consists of
contiguous data, the training partition will not always be completely contiguous. Fig 3
provides a visualization of what it means to partition time series data into contiguous
segments for the purposes of cross validation – for simplicity, here we show “5-fold CV”
rather than 10.
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Fig 4. Model Mwgpr: Our GPR ensemble’s predictions on data from patient
16.
3 Results
3.1 Cross Validation Results
In this section we will discuss the results of our models when evaluated with cross
validation on the dataset variants created. Again, 12 different learners were evaluated
(derived from 7 base learners) and 26 different dataset variants (De1 through De13, and
Da1 through Da13) were created for the purpose of this analysis. For each of the 47
patient histories not used for hyperparameter selection (described in Section 2.1), we
perform 10-fold CV using 12× 26 different learner/dataset-variant combinations to
determine their effectiveness and how well they compare to the baseline model, Mave
from Section 2.6.1. Appendix A.2 provides details about the models, and Appendix A.4
provides heat-maps that show both the performance of models on different datasets (in
terms of errL1 and errrLl), as well as the improved performance relative to Mave.
Appendix A.5 also shows the performance of these learned models in terms of other
measures.
For each learner and dataset variant pair, we compute the errL1 error as a
micro-average over all the records of each patient. These results allow us to determine
the pair with the lowest average errL1, over all 47 patient histories: These studies found
that Mwgpr had the lowest errL1 on average across all of the 26 different preprocessing
variants of the data. On dataset De1 (the preprocessing variant with the lowest average
errL1 across all models), Mave’s average errL1 was 2.91 mmol/L, while M
w
gpr’s average
errL1 was 2.70 mmol/L – i.e., our best model saw an improvement of only 7.1% relative
to the baseline!
To help understand why the improvement is not greater, Fig 4 shows the predictions
of Mwgpr for the processed entries from patient#16 that were used for selecting
hyperparameters. Here, we can see that the model is unable to account for the high
amount of variance present in the BG records for this patient.
Fig 5 plots the variance in each patient’s BG history and the corresponding patient’s
errL1 loss (Equations 4) that M
w
gpr was able to achieve. This figure shows that the
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Fig 5. Model Mwgpr: average errL1 as a function of BG variance, for all
patient histories.
variance of a patient’s blood glucose was highly correlated with the errL1 test loss (0.93
Pearson Correlation).
Fig 6 is a scatter plot of errL1 loss as a function of the number of data points that
were available for each patient in the dataset. This figure suggests that there is no
relationship between how well the model performs (in terms of errL1 test loss) on any
particular patient, and how many data points were collected from that patient –
Pearson Correlation: -0.14.
3.2 Other Evaluation Measures
We then considered the errrLl loss and found that M
w
gpr’s errrLl loss on De1 was 0.361.
We also saw that Mwgpr achieved the best errrLl, although this was on a different
dataset-variant. The best [model, dataset-variant] pair was Mwgpr on dataset De11,
which achieved an average errrLl error of 0.348; this was an improvement of 19.0%
relative to the Mavg baseline of 0.430. Note that M
w
gpr achieved an errL1 of 2.78
mmol/L dataset De11.
In addition to our errL1 and errrLl metrics we also report RMSE and the
glucose-specific versions of these metrics in Table 5. Interesting the best model across
all metrics was Mwgpr, and the best dataset preprocessing variant was either De1 or
De11 (both De variants).
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Fig 6. Model Mwgpr: average errL1 as a function of the # of diabetes diary
entries for a patient, for all patient histories.
Table 4. Performance of the best models across all metrics on De Datasets.
Metric Naive Model Error Best Model Error Percent Improvement Best Model Best Dataset Variant
RMSE 3.58 3.47 2.98% Mwgpr De1
errL1 (MAD) 2.91 2.70 7.12% M
w
gpr De1
errrLl (MARD) 0.430 0.348 18.97% M
w
gpr De11
gRMSE 5.01 4.86 2.95% Mwgpr De1
gMAD 5.31 4.98 6.28% Mwgpr De1
gMARD 0.783 0.648 17.28% Mwgpr De11
Note that these error values are micro-averages. These are selected entries from the tables in Supporting Information
Section A.5.
Table 5. Performance of the best models across all metrics on Da Datasets.
Metric Naive Model Error Best Model Error Percent Improvement Best Model Best Dataset Variant
RMSE 3.67 3.58 2.49% Mwgpr Da1
errL1 (MAD) 2.96 2.78 6.14% M
w
gpr Da1
errrLl (MARD) 0.422 0.355 15.88% M
w
gpr Da11
gRMSE 5.16 5.02 2.70% Mwgpr Da1
gMAD 5.45 5.14 5.70% Mwgpr Da1
gMARD 0.772 0.660 14.50% Mwgpr Da11
Note that these error values are micro-averages. These are selected entries from the tables in Supporting Information
Section A.5.
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4 Discussion
Our results show that our best learning algorithm is more accurate than a naive
baseline – but only slightly – and that it can only achieve an average errL1-loss of
approximately 2.70 mmol/L. This loss means that, on average, if the patient’s blood
glucose was normal (e.g., 6 mmol/L), the learned model may incorrectly identify the
patient as either hypoglycemic (as 6− 2.70 < 4 mmol/L) or hyperglycemic (6 + 2.70 > 8
mmol/L). Together with the strong relationship between glucose variance and
prediction error, this highlights how challenging it is to create models that produce
fine-grained blood glucose predictions when only using diabetes diary entries – i.e.,
using only the information that is commonly available to medical practitioners.
Having tried 312 different combinations of learners and dataset variants, and
observing minimal differences in their performance, it seems unlikely that another
[learner, dataset-variant] combination would be better. Note that these limited results
include models that use data from multiple patients, which suggest that simply
including more patients in the study is not likely to improve model performance.
Moreover, since the model accuracy did not seem to improve as the number of recorded
entries increased, we suspect that simply collecting more of these entries for each
individual will not improve model performance.
There are many possible reasons why modeling T1D glucose levels based on this
standard type of diabetes diary data is so challenging. It is possibly just an artifact of
our study: perhaps many of the patients who volunteered, did so because their diabetes
was difficult to manage. Another reason could be that inaccuracies and omissions of
variables in data prevent the model from producing accurate predictions. These
omissions could possibly include: not knowing the site where the bolus insulin was
injected, how much scar tissue was present at the injection site, skin temperature, how
accurately the carbohydrate value was recorded, the accuracy of the recorded insulin
dose, the levels of different hormones, whether the patient was menstruating, stress
levels, accuracy of recording exertion, insulin age or storage conditions, amount of blood
flow at the injection site and likely yet other factors. Given our belief that training
more accurate models will require additional relevant variables, future research might
incorporate more confounding variables, such as injection location [32], glucagon
levels [33] and/or meal protein/fat content [34]. However, it is not clear which, if any, of
such variables are sufficient to explain the response, nor whether they can be practically
captured in a clinical setting.
5 Conclusion
This work explored the challenge of accurately predicting future blood glucose values in
Type I diabetes patients, based on various models learning using several machine
learning algorithms. Our extensive explorations – involving 12 different learning
algorithms, and 26 different encodings of the data (312 combinations) – found that, on
average, the model with the lowest expected errL1 was a confidence weighted Gaussian
process regression model (Mwgpr). Using 10-fold cross validation on 29 601 blood glucose
records from 47 different patients, our Mwgpr model performed only 7.1% better than the
na¨ıve “mean predicting” model (Mavg). Anecdotally, a diabetologist also attempted to
do this task – predicting the BG for the next meal. We found that this model’s
predictions (insignificantly) outperformed the diabetologist’s, in terms of a simple
unbiased loss function, but that the diabetologist performed (insignificantly) better
when the evaluation was biased toward predicting hypoglycemic events; see Borle [25].
These results showed that our model could achieve an expected absolute error of
2.70 mmol/L (48.65 mg/dl), which is disconcertingly large given that this is based on
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the type of data that is frequently collected and used for clinical practice (records are
collected at meal times by the patients themselves). These results strongly suggest that
the standard data collected by T1D patients, while apparently appropriate for clinical
treatment of T1D, is not sufficient for accurately predicting blood glucose levels. We
conjecture that using patient data that is sampled more frequently and that includes
additional features would improve both the ability of professionals and machine learning
practitioners to more accurately predict patient’s blood glucose levels, but there is a
practical trade-off between patient convenience and highly detailed record keeping.
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Table 6. Description of Original and Processed Features used in this Study
meali The time of day: { Before Breakfast, After Breakfast, Before lunch, After Lunch,
Before Supper, After Supper, Before Bed, During the Night}
DOWi The day of the week
xVi Numeric encoding of exercise value: {2, 4, 7, 10}
PVi Pump Value: The rate at which the insulin pump is infusing (
units
hour
). This is always 0
if the patient does not have a pump
basali The units of background insulin injected
BGi The BG value at the current time (
mmol
L
)
IOBi Insulin on Board: Estimated residual insulin from the previous injection (
mmol
L
)
CHOi− The previous most recent amount of carbohydrates ingested (grams)
bolusi− The previous most recent amount of insulin injected (units)
BGi−CHO The BG value at the time that CHOi− was ingested (mmolL )
BGi−bolus The BG value at the time that bolusi− was injected (mmolL )
∆tCHOi The time between CHOi− and BGi+1 (min)
∆tbolusi The time between bolusi−and BGi+1 (min)
A Supporting Information
A.1 Dataset Preprocessing Variants and Example
As mentioned earlier, the features that we described in Section 2.2 are simplified so that
they can be easily understood. This appendix describes the complete set of features
that we used.
The previously described ∆ti and BGi features implicitly assume that the previous
event involved both injecting a quantity of insulin and also consuming some
carbohydrates. While this is typically the case, there are exceptions. To accommodate
such situations, where an event involves only one of these, we decompose each of these
terms into two different features: ∆ti is separated into ∆t
bolus
i and ∆t
CHO
i , and BGi is
separated into BGi
bolus and BGi
CHO. These correspond to the time since most recent
(previous) bolus injection ∆tbolusi (when bolusi− bolus units were injected and the
blood glucose was BGi
bolus), and the time since the most recent previous carbohydrate
consumption ∆tCHOi (when the subject consumed CHOi− and his/her blood glucose
was BGi
CHO).
Table 6 provides the complete set of features that we used and Table 7 provides the
correct version of Patient#16’s data from Table 3 with these features.
Table 8 lists all of the dataset variants that are generated by the various
feature-creation/selection steps. Note the first 13 datasets (De1 - De13) contain only
the subset of records that satisfy the EP criteria – see Section 2.3. The second 13 rows
(Da1 - Da13) deal with, essentially, the entire set of records. The “Missing Carbs” and
“Missing Bolus” columns address variants in handling missing data, “PCA
Transformation” indicates if the features were transformed using PCA, the “Kok
features” column indicates datasets that use the features described by Peter Kok and
the remaining columns indicate whether specific other features are included.
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Table 7. Example of Processed Data, over a single day, from Patient 16 (Variant D1)
index i 27 28 29 30 31 32
meali Before Breakfast After Breakfast Before Lunch After Lunch Before Dinner After Dinner
DOWi Tuesday Tuesday Tuesday Tuesday Tuesday Tuesday
EVi 4 4 4 4 4 4
PVi 0.50 0.50 0.63 0.45 0.90 0.90
basali 0 0 0 0 0 0
BGi 16.2 14.7 5.6 6.8 10.5 3.0
IOBi 0.00 7.90 3.61 0.89 0.81 3.35
CHOi− 17.5 30.0 20.5 30.0 18.5 15.0
bolusi− 1.93 10.40 2.44 3.00 2.54 3.80
BGi−CHO 10.3 16.2 14.7 5.6 6.8 10.5
BGi−bolus 10.3 16.2 14.7 5.6 6.8 10.5
∆tCHOi 540 103 120 196 187 89
∆tbolusi 540 103 120 196 187 89
Note that BGCHOi will differ from BG
bolus
i and ∆t
CHO
i will differ from ∆t
bolus
i whenever carbohydrates and insulin were not taken at
the same time.
Table 8. Datasets Generated from Different Feature Sets.
# of
Subjects
Records
Predicted
EP
Rules
DOW
Features
Basal
Feature
Patient
Specific
Features
Kok
Features
PCA
Transform
Missing
Carbs
Missing
Bolus
De1 42 7378 1 1 1 0 0 0 Throwout Impute Mean
De2 39 5978 1 1 1 0 0 0 Throwout Throwout
De3 47 16167 1 1 1 0 0 0 Impute Mean Impute 0
De4 47 16167 1 1 1 0 0 0 Impute 0 Impute Mean
De5 47 16167 1 7 1 1 0 0 Impute Mean Impute Mean
De6 47 16167 1 1 1 0 0 0 Impute Mean Impute Mean
De7 47 16167 1 7 1 0 0 0 Impute Mean Impute Mean
De8 47 16167 1 0 0 0 0 0 Impute Mean Impute Mean
De9 37 7349 1 0 0 0 1 0 N/A N/A
De10 47 16167 1 1 1 0 0 0 Impute 0 Impute 0
De11 45 10623 1 1 1 0 0 0 Impute Mean Throwout
De12 47 16167 1 0 0 0 0 1 Impute Mean Impute Mean
De13 37 7349 1 0 0 0 1 1 N/A N/A
Da1 42 15961 0 1 1 0 0 0 Throwout Impute Mean
Da2 39 13832 0 1 1 0 0 0 Throwout Throwout
Da3 47 24896 0 1 1 0 0 0 Impute Mean Impute 0
Da4 47 24896 0 1 1 0 0 0 Impute 0 Impute Mean
Da5 47 24896 0 7 1 1 0 0 Impute Mean Impute Mean
Da6 47 24896 0 1 1 0 0 0 Impute Mean Impute Mean
Da7 47 24896 0 7 1 0 0 0 Impute Mean Impute Mean
Da8 47 24896 0 0 0 0 0 0 Impute Mean Impute Mean
Da9 37 11888 0 0 0 0 1 0 N/A N/A
Da10 47 24896 0 1 1 0 0 0 Impute 0 Impute 0
Da11 45 19122 0 1 1 0 0 0 Impute Mean Throwout
Da12 47 24896 0 0 0 0 0 1 Impute Mean Impute Mean
Da13 37 11888 0 0 0 0 1 1 N/A N/A
Here, “Basal feature” and “Patient Specific Features” are features that were included (1) or excluded (0) from datasets.
“DOW Features” indicates if the day of the week was not included (0), included (1), or included as a one hot encoded feature
(7). “PCA Transform” indicates whether the data was reduced to 4 principle components. “Kok Features” means that the
data was preprocessed to replicate (as best as possible) the features used in Kok’s MSc thesis [2]. In the final two columns,
the value “Throwout” means that these records were removed from the dataset. The “# of Subjects” column shows that some
datasets did not include all (47) patients. In these cases, patients were excluded because they had too few records (under 100)
after the preprocessing steps were applied to their data. The table is partitioned so that datasets with the EP rules (De1 –
De13) precede their corresponding datasets without EP rules (Da1 – Da13).
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Fig 7. Target errrLl Loss Function. This function emphasizes loss when the model
fails to predict hypoglycemic events. Here, “True BG” refers to BGi+1 and “Predicted
BG” refers to B̂Gi+1 = M(xi, ∆ti+1 ). Note that the error is large when the true BG
is very low, but the predicted B̂G is relatively high.
A.2 Model Variants
Table 9. Descriptions of the Different Learners Used.
name Symbol Algorithm Confidence Weighting Stacking
gpr be Mwgpr GPR 1 0
gpr be AllPat AllMeals Mwsgpr GPR 1 1
gpr IndPat AllMeals Mgpr GPR 0 0
gpr AllPat AllMeals Msgpr GPR 0 1
svr1 Msvr SVR (RBF Kernel) 0 0
svr1 lin M linsvr SVR (Linear Kernel) 0 0
svr1 allpats Mssvr SVR (RBF Kernel) 0 1
rf4 Mrf Random Forest 0 0
KNN10U Mknn KNN 0 0
ridge Mridge Ridge Regression 0 0
wnn Mwnn Wavelet Neural Network 0 0
NN Mnn Feed-Forward NN 0 0
naive Mavg BG History Average 0 0
Confidence Weighting is explained in Section 2.5.1 and Stacking is explained in Appendix A.6.
A.3 Inclusion of errrLl in addition to errL1
While errL1 is the standard loss function, it can be problematic: Note the [predicted,
true] pair [M(x1, ∆t2), BG2] = [5, 3] and [M(x3, ∆t4), BG4] = [10, 12] each have
an errL1 of 2 – i.e., |M(x1,∆t2)−BG2| = 2 = |M(x3,∆t4)−BG4| – but predicting 5
mmol/L instead of 3 mmol/L is potentially much more dangerous, in terms of patient
health, than predicting 10 mmol/L instead of 12 mmol/L. Here, the errrLl function
would correctly impose a larger penalty to the first |M(x1,∆t2)−BG2|BG2 =
2
3 versus the
second |M(x3,∆t4)−BG4|BG4 =
2
12 . See Fig 7 for a visualization of the errrLl function,
showing that this error is especially large in the dangerous situation when the true value
BG is small but the predicted value M(x,∆t) is large.
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A.4 Experimental Results: Heat-Maps
This sub-appendix provides a set of heat-maps (Figs 8, 9, 10 and 11). The left half of
each heat-map contains the datasets that adhere to our EP rules, while the right half
contains those datasets that do not. Models (on the y axis) are sorted in terms of their
average errL1 error (over all 26 datasets), so that the model with the best average errL1
error across all datasets appears at the top of these figures. Further, datasets De1 to
De13 and Da1 to Da13 (in each half of these heat maps) are sorted horizontally, in
increasing order of average errL1 error across all models, with the left most dataset in
each half having the smallest error. In Figure 8, the best model/dataset combination is
found in the top left corner. More detailed results for these heat-maps are seen in
Borle [25].
Fig 8. Average L1 Loss: Datasets vs. Models. Datasets using the EP criteria
are on the left half of the bisecting white line. Each square represents the
cross-validation L1 error, micro-averaged over patients.
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Fig 9. Percent Improvement in Average L1 Loss for Models vs. Baseline.
Datasets using the EP criteria are on the left half of the bisecting white line. Each
square corresponds with the percent change between the corresponding result in
Figure 8 and the performance of Mave.
Fig 10. Average Relative L1 Loss: Datasets vs. Models. Datasets using the
EP criteria are on the left half of the bisecting white line. Each square represents the
cross-validation relative L1 error, micro-averaged over patients.
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Fig 11. Percent Improvement in Average Relative L1 Loss for Models vs.
Baseline. Datasets using the EP criteria are on the left half of the bisecting white line.
Each square corresponds with the percent change between the corresponding result in
Figure 10 and the performance of Mave.
A.5 Experimental Results: Tables
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Table 10. Losses Corresponding to Fig 8.
Mwgpr M
ws
gpr Mgpr M
s
gpr Mrf Msvr M
lin
svr Mknn M
s
svr Mridge Mwnn Mnn
De1 2.7 2.71 2.74 2.75 2.74 2.8 2.81 2.8 2.86 2.87 2.88 3.29
De2 2.79 2.79 2.82 2.83 2.83 2.88 2.9 2.88 2.91 2.93 2.95 3.8
De3 2.78 2.79 2.81 2.82 2.84 2.86 2.89 2.89 2.96 3.0 3.01 3.22
De4 2.79 2.79 2.82 2.82 2.84 2.86 2.9 2.89 2.97 3.0 3.01 3.37
De5 2.81 2.82 2.85 2.86 2.84 2.88 2.9 2.9 2.96 2.99 3.0 3.14
De6 2.78 2.78 2.81 2.81 2.83 2.84 2.89 2.88 2.96 2.98 3.01 3.2
De7 2.81 2.82 2.85 2.86 2.84 2.9 2.9 2.9 2.96 2.99 2.99 3.16
De8 2.79 2.79 2.82 2.82 2.84 2.84 2.9 2.9 2.97 3.0 3.0 3.44
De9 2.82 2.82 2.84 2.84 2.84 2.94 2.9 2.99 2.94 2.93 2.95 3.9
De10 2.82 2.83 2.86 2.86 2.87 2.91 2.92 2.92 2.98 3.0 3.02 3.31
De11 2.78 2.79 2.84 2.85 2.85 2.89 2.93 2.92 2.99 3.05 3.05 3.61
De12 2.84 2.84 2.87 2.88 2.88 2.87 2.93 2.93 2.99 3.03 3.0 3.64
De13 2.82 2.82 2.83 2.84 2.88 2.9 2.89 2.98 2.95 2.94 2.96 29.04
Da1 2.78 2.78 2.83 2.83 2.82 2.9 2.9 2.89 2.94 2.97 2.99 3.58
Da2 2.86 2.86 2.9 2.9 2.91 2.97 2.97 2.96 3.0 3.03 3.05 3.83
Da3 2.89 2.9 2.92 2.93 2.94 2.97 3.0 3.01 3.07 3.12 3.12 3.47
Da4 2.9 2.9 2.93 2.93 2.93 2.98 3.01 3.02 3.07 3.11 3.13 3.48
Da5 2.92 2.93 2.96 2.97 2.93 3.01 3.03 3.02 3.07 3.1 3.12 3.35
Da6 2.89 2.89 2.92 2.92 2.93 2.96 3.01 3.01 3.07 3.1 3.12 3.61
Da7 2.92 2.93 2.96 2.97 2.93 3.02 3.03 3.02 3.07 3.1 3.11 3.38
Da8 2.89 2.9 2.92 2.93 2.93 2.95 3.02 3.02 3.07 3.11 3.12 3.77
Da9 2.87 2.87 2.89 2.89 2.91 3.0 2.97 3.09 3.0 3.0 3.0 4.14
Da10 2.93 2.93 2.96 2.96 2.97 3.02 3.03 3.04 3.08 3.12 3.15 3.53
Da11 2.9 2.9 2.95 2.96 2.96 3.0 3.02 3.1 3.12 3.16 3.17 4.22
Da12 2.94 2.94 2.97 2.97 2.96 2.98 3.03 3.05 3.09 3.13 3.12 4.7
Da13 2.87 2.87 2.89 2.89 2.94 2.96 2.95 3.06 3.01 3.0 3.01 6.1
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 11. Percentage Improvements Corresponding to Fig 9.
Mwgpr M
ws
gpr Mgpr M
s
gpr Mrf Msvr M
lin
svr Mridge Mknn M
s
svr Mwnn Mnn
De1 7.12 7.02 5.75 5.54 5.95 3.73 3.58 3.77 1.8 1.45 1.11 -13.15
De2 6.19 6.14 5.02 4.8 4.62 2.93 2.28 3.18 1.97 1.48 0.85 -27.86
De3 7.98 7.85 6.96 6.83 6.03 5.51 4.43 4.6 1.98 0.88 0.56 -6.35
De4 7.79 7.74 6.82 6.75 6.07 5.47 4.26 4.44 1.66 0.87 0.39 -11.52
De5 7.01 6.82 5.86 5.59 6.13 4.61 4.02 4.27 2.19 1.05 0.69 -3.69
De6 8.18 8.02 7.23 6.98 6.34 6.09 4.38 4.62 2.24 1.3 0.48 -5.91
De7 7.01 6.76 5.86 5.57 6.2 4.25 4.02 4.27 2.19 1.19 0.98 -4.47
De8 7.93 7.8 6.91 6.73 6.04 6.27 4.06 3.99 1.9 0.73 0.94 -13.7
De9 4.2 4.15 3.5 3.49 3.39 0.11 1.42 -1.55 0.01 0.16 -0.23 -32.75
De10 6.65 6.48 5.57 5.38 5.06 3.62 3.33 3.51 1.33 0.75 0.09 -9.39
De11 9.94 9.72 8.04 7.61 7.61 6.47 5.15 5.33 3.11 1.09 1.23 -16.83
De12 6.27 6.03 5.0 4.71 4.96 4.99 3.17 2.85 1.29 -0.13 0.72 -20.35
De13 4.1 3.99 3.7 3.53 2.15 1.19 1.8 -1.24 -0.4 -0.18 -0.75 -887.75
Da1 6.14 6.08 4.63 4.49 4.79 2.14 2.13 2.37 0.9 -0.18 -0.73 -20.68
Da2 4.97 4.9 3.69 3.53 3.31 1.27 1.31 1.59 0.5 -0.53 -1.49 -27.2
Da3 7.02 6.97 6.1 6.0 5.62 4.57 3.54 3.27 1.42 -0.06 -0.26 -11.37
Da4 6.9 6.86 5.91 5.83 5.78 4.42 3.34 2.97 1.35 -0.01 -0.52 -11.91
Da5 6.07 5.93 4.84 4.61 6.04 3.33 2.83 2.84 1.49 0.28 -0.28 -7.63
Da6 7.23 7.07 6.34 6.1 5.96 4.96 3.43 3.27 1.51 0.38 -0.12 -15.97
Da7 6.07 5.9 4.84 4.59 6.05 2.89 2.83 2.84 1.49 0.35 0.06 -8.41
Da8 7.13 6.93 6.22 5.97 5.84 5.4 3.13 2.99 1.33 -0.01 -0.03 -20.94
Da9 4.21 4.2 3.29 3.25 2.8 -0.19 0.56 -3.19 -0.22 -0.15 -0.16 -38.48
Da10 5.95 5.85 4.92 4.79 4.73 3.05 2.72 2.46 0.93 -0.17 -1.19 -13.24
Da11 7.91 7.81 6.26 5.99 6.17 4.73 4.22 1.68 1.1 -0.39 -0.74 -34.05
Da12 5.64 5.53 4.66 4.49 4.8 4.47 2.55 2.15 0.75 -0.59 -0.27 -51.06
Da13 4.11 4.0 3.51 3.36 1.62 1.1 1.47 -2.33 -0.69 -0.46 -0.61 -103.85
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 12. Losses Corresponding to Fig 10.
Mwgpr M
ws
gpr Mgpr Mrf M
s
gpr Mridge Mknn Msvr M
s
svr Mwnn M
lin
svr Mnn
De1 3.61 3.61 3.65 3.64 3.66 3.76 3.81 3.81 3.9 3.95 3.88 4.62
De2 3.62 3.62 3.68 3.65 3.69 3.77 3.78 3.82 3.89 3.97 3.9 4.6
De3 3.67 3.67 3.71 3.75 3.72 3.83 3.91 3.88 3.99 4.0 3.99 4.28
De4 3.67 3.68 3.72 3.75 3.72 3.84 3.92 3.88 3.99 4.02 3.99 4.3
De5 3.71 3.72 3.77 3.74 3.78 3.85 3.89 3.93 3.98 4.01 4.0 4.24
De6 3.66 3.67 3.7 3.74 3.72 3.83 3.89 3.85 3.96 4.03 3.99 4.27
De7 3.71 3.73 3.77 3.73 3.78 3.85 3.89 3.93 3.97 4.0 4.0 4.26
De8 3.67 3.68 3.71 3.75 3.72 3.86 3.91 3.85 3.99 4.02 4.02 4.37
De9 3.58 3.58 3.6 3.6 3.6 3.77 3.74 3.81 3.71 3.74 3.79 4.79
De10 3.73 3.74 3.78 3.8 3.79 3.87 3.94 3.98 3.99 4.03 4.02 4.41
De11 3.48 3.5 3.57 3.57 3.59 3.69 3.74 3.72 3.86 3.85 3.84 4.68
De12 3.75 3.76 3.8 3.8 3.81 3.89 3.95 3.93 4.03 4.0 4.05 4.73
De13 3.58 3.58 3.59 3.64 3.6 3.77 3.77 3.77 3.73 3.76 3.77 6.02
Da1 3.64 3.64 3.71 3.68 3.72 3.81 3.89 3.9 3.91 3.93 3.95 4.73
Da2 3.62 3.62 3.67 3.66 3.67 3.75 3.8 3.86 3.81 3.85 3.88 4.73
Da3 3.75 3.75 3.78 3.79 3.79 3.9 3.98 3.97 4.03 4.06 4.05 4.66
Da4 3.75 3.75 3.79 3.79 3.79 3.91 3.98 3.98 4.03 4.08 4.06 4.82
Da5 3.79 3.79 3.84 3.79 3.85 3.92 3.96 4.02 4.02 4.07 4.08 4.45
Da6 3.74 3.74 3.77 3.78 3.78 3.9 3.96 3.95 4.01 4.06 4.05 4.63
Da7 3.79 3.8 3.84 3.78 3.85 3.92 3.96 4.03 4.02 4.04 4.08 4.48
Da8 3.75 3.75 3.78 3.8 3.79 3.93 3.98 3.94 4.03 4.09 4.09 4.78
Da9 3.63 3.63 3.66 3.69 3.66 3.88 3.81 3.87 3.78 3.84 3.88 5.35
Da10 3.8 3.8 3.84 3.82 3.85 3.93 4.0 4.05 4.04 4.05 4.09 4.68
Da11 3.55 3.56 3.61 3.6 3.62 3.73 3.78 3.78 3.83 3.88 3.84 4.73
Da12 3.82 3.82 3.86 3.85 3.87 3.97 4.02 4.01 4.06 4.07 4.13 11.06
Da13 3.63 3.64 3.65 3.72 3.66 3.86 3.84 3.82 3.8 3.85 3.85 7.52
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models. Here all values are multiplied
by 10 so that they are the same order of magnitude as in Table 20.
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Table 13. Percentage Improvements Corresponding to Fig 11.
Mwgpr M
ws
gpr Mgpr Mrf M
s
gpr Mridge Mknn Msvr M
s
svr M
lin
svr Mwnn Mnn
De1 17.53 17.45 16.52 16.76 16.33 14.19 12.9 12.99 10.96 11.37 9.68 -5.64
De2 16.69 16.63 15.34 16.03 15.13 13.16 12.99 12.06 10.56 10.16 8.59 -5.95
De3 17.97 17.79 16.9 16.16 16.71 14.2 12.47 13.16 10.83 10.76 10.4 4.17
De4 17.81 17.73 16.79 16.15 16.72 14.04 12.3 13.13 10.73 10.78 10.07 3.82
De5 16.91 16.73 15.64 16.42 15.39 13.89 13.0 12.14 10.87 10.58 10.32 5.19
De6 18.16 17.95 17.16 16.34 16.86 14.21 13.01 13.76 11.31 10.79 9.93 4.5
De7 16.91 16.64 15.64 16.43 15.32 13.89 13.0 11.96 11.1 10.58 10.39 4.67
De8 17.85 17.7 16.92 16.07 16.73 13.59 12.45 13.77 10.69 10.16 10.12 2.34
De9 12.68 12.61 12.07 12.09 12.06 7.84 8.65 7.01 9.38 7.43 8.72 -16.97
De10 16.57 16.38 15.46 14.89 15.26 13.36 11.91 11.01 10.62 10.03 9.82 1.38
De11 18.97 18.7 16.87 16.89 16.42 14.1 12.95 13.47 10.26 10.72 10.5 -8.95
De12 16.13 15.86 15.06 14.9 14.73 12.82 11.7 12.11 9.8 9.42 10.51 -5.72
De13 12.65 12.49 12.27 11.01 12.06 7.96 7.93 7.99 9.01 7.83 8.31 -46.92
Da1 15.85 15.83 14.3 14.9 14.17 12.11 10.15 9.93 9.79 8.86 9.22 -9.33
Da2 13.7 13.63 12.54 12.67 12.41 10.56 9.29 7.96 9.05 7.39 8.14 -12.83
Da3 16.61 16.54 15.77 15.59 15.66 13.19 11.36 11.66 10.18 9.73 9.56 -3.7
Da4 16.55 16.5 15.63 15.71 15.56 13.02 11.39 11.41 10.22 9.71 9.15 -7.34
Da5 15.68 15.54 14.52 15.67 14.31 12.76 11.85 10.45 10.48 9.26 9.36 0.96
Da6 16.84 16.65 16.03 15.85 15.76 13.17 11.84 12.02 10.71 9.75 9.58 -3.01
Da7 15.68 15.51 14.52 15.91 14.28 12.76 11.85 10.18 10.62 9.26 10.0 0.23
Da8 16.64 16.43 15.83 15.36 15.59 12.6 11.44 12.2 10.29 9.07 9.0 -6.37
Da9 12.88 12.89 12.11 11.57 12.1 6.83 8.53 7.19 9.21 6.86 7.8 -28.32
Da10 15.47 15.35 14.51 14.86 14.38 12.45 11.04 9.85 10.0 9.02 9.74 -4.16
Da11 15.88 15.74 14.61 14.71 14.33 11.55 10.49 10.47 9.25 9.15 8.15 -11.98
Da12 15.02 14.9 14.15 14.34 13.95 11.59 10.63 10.81 9.73 7.97 9.49 -146.23
Da13 12.89 12.76 12.47 10.71 12.29 7.49 7.98 8.28 8.85 7.64 7.68 -80.39
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 14. Losses Using gMAD.
Msvr M
w
gpr M
ws
gpr Mrf Mgpr M
s
gpr M
lin
svr Mridge Mknn M
s
svr Mwnn Mnn
De1 5.03 4.98 4.99 5.05 5.08 5.09 5.12 5.19 5.24 5.37 5.38 5.75
De2 5.13 5.09 5.09 5.18 5.17 5.17 5.21 5.26 5.28 5.4 5.42 6.43
De3 5.16 5.19 5.2 5.31 5.25 5.26 5.32 5.41 5.48 5.69 5.68 5.68
De4 5.16 5.2 5.21 5.31 5.26 5.26 5.33 5.42 5.49 5.7 5.7 6.1
De5 5.21 5.25 5.26 5.3 5.32 5.33 5.33 5.41 5.47 5.6 5.7 5.58
De6 5.13 5.17 5.18 5.29 5.23 5.25 5.32 5.41 5.47 5.65 5.68 5.67
De7 5.22 5.25 5.27 5.3 5.32 5.33 5.33 5.41 5.47 5.62 5.66 5.63
De8 5.14 5.2 5.21 5.31 5.27 5.28 5.36 5.47 5.5 5.67 5.66 5.97
De9 5.2 5.18 5.18 5.17 5.22 5.22 5.15 5.32 5.34 5.49 5.46 6.4
De10 5.27 5.27 5.28 5.37 5.34 5.35 5.4 5.48 5.51 5.7 5.71 5.82
De11 5.1 5.08 5.09 5.2 5.18 5.2 5.23 5.33 5.41 5.63 5.59 6.04
De12 5.25 5.33 5.34 5.39 5.42 5.43 5.46 5.56 5.54 5.69 5.68 6.37
De13 5.15 5.18 5.18 5.23 5.21 5.22 5.23 5.4 5.35 5.49 5.49 31.86
Da1 5.2 5.14 5.14 5.19 5.25 5.25 5.29 5.36 5.4 5.6 5.61 6.17
Da2 5.28 5.23 5.23 5.3 5.32 5.33 5.33 5.42 5.44 5.63 5.65 6.44
Da3 5.36 5.4 5.41 5.48 5.47 5.47 5.52 5.64 5.7 5.94 5.94 6.09
Da4 5.37 5.41 5.41 5.47 5.48 5.49 5.53 5.65 5.69 5.95 5.92 6.11
Da5 5.43 5.46 5.47 5.46 5.55 5.57 5.55 5.65 5.69 5.86 5.93 5.91
Da6 5.34 5.38 5.4 5.46 5.45 5.47 5.52 5.64 5.69 5.91 5.89 6.2
Da7 5.45 5.46 5.48 5.45 5.55 5.57 5.55 5.65 5.69 5.88 5.91 5.93
Da8 5.33 5.4 5.41 5.47 5.47 5.48 5.57 5.68 5.7 5.92 5.92 6.42
Da9 5.33 5.28 5.28 5.33 5.34 5.34 5.29 5.49 5.47 5.62 5.57 6.81
Da10 5.46 5.47 5.48 5.53 5.55 5.56 5.58 5.69 5.72 5.95 5.99 6.18
Da11 5.3 5.29 5.3 5.38 5.41 5.42 5.38 5.59 5.67 5.88 5.84 6.79
Da12 5.42 5.52 5.53 5.55 5.6 5.61 5.64 5.76 5.74 5.93 5.93 7.73
Da13 5.26 5.28 5.28 5.37 5.32 5.33 5.35 5.55 5.49 5.61 5.58 9.04
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 15. Percentage Improvements for gMAD.
Msvr M
w
gpr M
ws
gpr Mrf Mgpr M
s
gpr M
lin
svr Mridge Mknn M
s
svr Mwnn Mnn
De1 5.41 6.28 6.19 5.07 4.43 4.23 3.73 2.35 1.39 -1.0 -1.15 -8.12
De2 3.29 4.02 4.01 2.45 2.62 2.46 1.8 0.91 0.57 -1.73 -2.17 -21.15
De3 7.47 6.9 6.69 4.73 5.81 5.67 4.52 2.93 1.7 -2.08 -1.95 -1.99
De4 7.38 6.68 6.57 4.77 5.61 5.56 4.36 2.81 1.46 -2.23 -2.35 -9.52
De5 6.58 5.81 5.56 4.97 4.6 4.28 4.44 2.85 1.8 -0.43 -2.27 -0.07
De6 8.03 7.2 6.97 5.07 6.17 5.89 4.6 3.02 1.83 -1.37 -2.0 -1.82
De7 6.41 5.81 5.5 4.94 4.6 4.29 4.44 2.85 1.8 -0.76 -1.49 -1.1
De8 7.78 6.72 6.59 4.72 5.5 5.35 3.79 1.92 1.37 -1.62 -1.41 -7.01
De9 1.36 1.79 1.72 1.85 1.0 0.98 2.23 -0.93 -1.26 -4.19 -3.6 -21.35
De10 5.43 5.4 5.19 3.63 4.19 3.97 3.16 1.7 1.06 -2.32 -2.54 -4.43
De11 6.54 6.94 6.73 4.74 5.03 4.65 4.09 2.35 0.87 -3.16 -2.35 -10.64
De12 5.9 4.49 4.31 3.27 2.85 2.61 2.07 0.07 0.59 -2.08 -1.9 -14.29
De13 2.37 1.79 1.68 0.82 1.28 1.07 0.85 -2.49 -1.47 -4.03 -4.12 -504.3
Da1 4.59 5.7 5.67 4.83 3.76 3.63 2.95 1.58 0.85 -2.83 -2.89 -13.21
Da2 2.45 3.29 3.27 1.98 1.65 1.52 1.47 -0.14 -0.62 -4.07 -4.34 -19.05
Da3 6.94 6.24 6.14 4.87 5.08 4.98 4.09 2.07 1.11 -3.21 -3.06 -5.73
Da4 6.72 6.07 6.0 5.07 4.83 4.76 3.92 1.89 1.25 -3.23 -2.81 -6.07
Da5 5.64 5.15 4.96 5.24 3.63 3.35 3.71 1.89 1.24 -1.71 -3.0 -2.58
Da6 7.35 6.51 6.29 5.18 5.41 5.11 4.08 2.12 1.24 -2.56 -2.34 -7.68
Da7 5.37 5.15 4.9 5.31 3.63 3.32 3.71 1.89 1.24 -2.0 -2.67 -2.94
Da8 7.5 6.22 6.05 5.11 5.07 4.84 3.38 1.36 0.99 -2.66 -2.81 -11.38
Da9 1.14 2.03 2.02 1.13 0.88 0.85 1.73 -1.85 -1.55 -4.29 -3.46 -26.43
Da10 5.21 5.02 4.88 3.9 3.69 3.53 3.09 1.23 0.75 -3.36 -4.06 -7.38
Da11 5.62 5.66 5.6 4.15 3.63 3.38 4.11 0.35 -1.02 -4.77 -4.08 -21.08
Da12 5.98 4.13 4.07 3.76 2.86 2.7 2.16 -0.08 0.3 -2.92 -2.91 -34.21
Da13 2.3 2.05 1.96 0.35 1.25 1.06 0.72 -3.01 -1.83 -4.22 -3.55 -67.75
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 16. Losses Using gMARD
Mwgpr M
ws
gpr Mrf Mgpr M
s
gpr Msvr Mridge Mknn M
lin
svr M
s
svr Mwnn Mnn
De1 6.88 6.89 6.95 7.01 7.02 7.1 7.22 7.23 7.38 7.58 7.68 8.63
De2 6.74 6.74 6.78 6.88 6.89 6.97 7.06 6.96 7.21 7.33 7.44 7.99
De3 7.1 7.12 7.29 7.21 7.23 7.32 7.49 7.51 7.7 7.88 7.9 7.94
De4 7.12 7.13 7.27 7.22 7.23 7.33 7.5 7.52 7.7 7.9 7.92 7.92
De5 7.2 7.23 7.25 7.33 7.35 7.41 7.5 7.47 7.69 7.75 7.94 7.89
De6 7.08 7.1 7.28 7.18 7.21 7.27 7.49 7.47 7.69 7.81 7.94 7.89
De7 7.2 7.23 7.25 7.33 7.36 7.41 7.5 7.47 7.69 7.76 7.91 7.94
De8 7.13 7.14 7.3 7.23 7.24 7.3 7.58 7.54 7.79 7.84 7.93 8.11
De9 6.65 6.66 6.64 6.71 6.71 6.85 6.83 6.9 6.87 7.04 7.04 8.11
De10 7.24 7.26 7.4 7.35 7.37 7.53 7.57 7.55 7.78 7.91 7.96 8.22
De11 6.48 6.5 6.63 6.64 6.67 6.74 6.87 6.86 7.05 7.22 7.19 7.91
De12 7.33 7.34 7.42 7.45 7.48 7.5 7.69 7.62 7.92 7.88 7.91 8.64
De13 6.65 6.66 6.71 6.68 6.7 6.77 6.94 6.94 6.95 7.03 7.04 9.39
Da1 6.97 6.97 7.01 7.15 7.16 7.28 7.33 7.44 7.51 7.67 7.68 8.48
Da2 6.75 6.75 6.8 6.87 6.88 7.03 7.01 7.06 7.16 7.24 7.28 8.2
Da3 7.26 7.27 7.34 7.35 7.37 7.48 7.61 7.69 7.82 8.01 8.05 8.53
Da4 7.26 7.27 7.33 7.37 7.38 7.51 7.62 7.66 7.82 8.02 8.07 8.63
Da5 7.35 7.37 7.34 7.48 7.51 7.6 7.63 7.63 7.84 7.88 8.08 8.23
Da6 7.23 7.25 7.32 7.32 7.35 7.45 7.61 7.63 7.81 7.95 8.04 8.44
Da7 7.35 7.37 7.32 7.48 7.51 7.6 7.63 7.63 7.84 7.9 8.0 8.3
Da8 7.27 7.29 7.36 7.36 7.39 7.46 7.7 7.68 7.91 7.96 8.08 8.65
Da9 6.81 6.81 6.85 6.89 6.88 7.02 7.06 7.1 7.08 7.23 7.28 9.06
Da10 7.37 7.38 7.41 7.48 7.5 7.66 7.68 7.69 7.89 8.03 8.03 8.57
Da11 6.6 6.61 6.67 6.72 6.73 6.84 6.9 6.98 7.02 7.22 7.26 8.05
Da12 7.46 7.47 7.47 7.57 7.59 7.63 7.83 7.76 8.06 7.98 8.03 15.13
Da13 6.8 6.81 6.91 6.84 6.86 6.94 7.14 7.13 7.14 7.24 7.27 11.0
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models. Here all values are multiplied
by 10 so that they are the same order of magnitude as in Table 20.
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Table 17. Percentage Improvements Corresponding to gMARD.
Mwgpr M
ws
gpr Mrf Mgpr M
s
gpr Msvr Mridge Mknn M
lin
svr M
s
svr Mwnn Mnn
De1 18.38 18.28 17.53 16.81 16.63 15.73 14.29 14.18 12.44 10.05 8.87 -2.41
De2 16.37 16.35 15.83 14.59 14.45 13.49 12.39 13.57 10.54 9.04 7.65 0.76
De3 18.29 18.02 16.06 17.05 16.85 15.71 13.76 13.52 11.37 9.33 9.13 8.61
De4 18.08 17.93 16.27 16.88 16.81 15.58 13.64 13.5 11.41 9.05 8.86 8.86
De5 17.09 16.84 16.54 15.64 15.36 14.67 13.67 14.06 11.49 10.84 8.65 9.22
De6 18.56 18.27 16.22 17.41 17.04 16.32 13.84 14.03 11.52 10.12 8.66 9.18
De7 17.09 16.76 16.52 15.64 15.29 14.69 13.67 14.06 11.49 10.64 9.0 8.61
De8 18.03 17.84 16.03 16.84 16.66 15.98 12.77 13.29 10.41 9.84 8.82 6.75
De9 11.56 11.47 11.72 10.82 10.81 8.9 9.18 8.32 8.65 6.42 6.37 -7.75
De10 16.68 16.43 14.87 15.38 15.14 13.35 12.84 13.07 10.46 8.98 8.36 5.35
De11 17.28 17.02 15.34 15.17 14.77 13.99 12.29 12.4 10.01 7.78 8.15 -1.04
De12 15.72 15.51 14.61 14.26 13.98 13.72 11.35 12.34 8.88 9.35 9.02 0.62
De13 11.65 11.47 10.81 11.15 10.89 10.0 7.79 7.81 7.65 6.49 6.36 -24.83
Da1 16.96 16.95 16.46 14.85 14.73 13.24 12.71 11.35 10.48 8.62 8.47 -1.04
Da2 13.43 13.42 12.78 11.9 11.81 9.83 10.13 9.48 8.2 7.1 6.7 -5.09
Da3 17.1 16.98 16.09 15.98 15.85 14.53 13.05 12.19 10.66 8.47 8.07 2.52
Da4 17.01 16.91 16.24 15.78 15.7 14.16 12.98 12.52 10.69 8.41 7.86 1.39
Da5 16.03 15.84 16.12 14.5 14.25 13.2 12.82 12.88 10.45 9.93 7.74 5.95
Da6 17.39 17.13 16.38 16.33 15.98 14.92 13.08 12.85 10.77 9.23 8.2 3.61
Da7 16.03 15.8 16.41 14.5 14.21 13.12 12.82 12.88 10.46 9.72 8.63 5.17
Da8 16.99 16.8 15.89 15.89 15.65 14.8 12.08 12.32 9.68 9.12 7.73 1.19
Da9 11.96 11.98 11.45 10.97 10.98 9.21 8.7 8.14 8.49 6.45 5.81 -17.13
Da10 15.81 15.63 15.32 14.5 14.34 12.46 12.3 12.11 9.85 8.22 8.2 2.13
Da11 14.5 14.4 13.59 13.04 12.79 11.45 10.59 9.64 9.07 6.54 6.03 -4.28
Da12 14.74 14.69 14.68 13.53 13.36 12.81 10.49 11.35 7.94 8.88 8.34 -72.84
Da13 12.11 11.99 10.67 11.53 11.32 10.31 7.69 7.8 7.65 6.43 6.01 -42.24
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 18. Losses Using RMSE.
Mwgpr M
ws
gpr Mgpr M
s
gpr Mrf Msvr M
lin
svr Mknn Mwnn M
s
svr Mridge Mnn
De1 3.47 3.47 3.52 3.53 3.52 3.59 3.57 3.66 3.64 3.64 3.58 4.37
De2 3.57 3.57 3.6 3.61 3.63 3.69 3.75 3.73 3.72 3.7 3.65 6.71
De3 3.59 3.6 3.62 3.63 3.66 3.66 3.67 3.81 3.83 3.84 3.69 4.24
De4 3.6 3.6 3.63 3.63 3.66 3.67 3.68 3.83 3.85 3.84 3.7 6.02
De5 3.63 3.63 3.66 3.67 3.66 3.69 3.69 3.81 3.83 3.85 3.71 4.17
De6 3.59 3.59 3.61 3.62 3.65 3.65 3.68 3.81 3.84 3.83 3.7 4.35
De7 3.63 3.63 3.66 3.67 3.66 3.71 3.69 3.81 3.81 3.84 3.71 4.24
De8 3.6 3.6 3.63 3.63 3.66 3.65 3.69 3.82 3.83 3.86 3.72 5.76
De9 3.64 3.64 3.66 3.66 3.66 3.76 3.74 3.78 3.78 3.77 4.73 5.94
De10 3.64 3.64 3.67 3.68 3.69 3.73 3.71 3.84 3.86 3.84 3.73 4.6
De11 3.58 3.58 3.63 3.65 3.66 3.68 3.7 3.82 3.85 3.88 3.72 6.61
De12 3.65 3.65 3.69 3.7 3.7 3.68 3.72 3.84 3.84 3.88 3.75 6.07
De13 3.64 3.64 3.65 3.65 3.71 3.71 3.69 3.78 3.8 3.78 4.52 254.95
Da1 3.58 3.58 3.63 3.63 3.63 3.71 3.71 3.76 3.81 3.78 3.71 5.56
Da2 3.66 3.66 3.7 3.71 3.72 3.78 3.82 3.83 3.87 3.85 3.78 6.48
Da3 3.72 3.73 3.75 3.76 3.78 3.8 3.82 3.94 3.99 3.99 3.95 5.01
Da4 3.73 3.73 3.76 3.77 3.78 3.81 3.83 3.94 3.99 3.98 4.11 5.17
Da5 3.76 3.76 3.8 3.81 3.77 3.85 3.86 3.94 3.98 3.99 3.96 5.04
Da6 3.72 3.72 3.75 3.76 3.77 3.79 3.83 3.94 3.98 3.98 3.94 6.64
Da7 3.76 3.77 3.8 3.81 3.77 3.87 3.86 3.94 3.97 3.98 3.96 5.02
Da8 3.72 3.73 3.75 3.76 3.78 3.78 3.84 3.95 3.98 3.99 3.88 9.06
Da9 3.7 3.7 3.73 3.73 3.74 3.84 3.84 3.86 3.85 3.84 5.16 7.55
Da10 3.76 3.77 3.8 3.8 3.81 3.86 3.85 3.96 4.02 3.98 4.07 5.7
Da11 3.71 3.71 3.77 3.78 3.78 3.82 3.83 3.98 4.01 4.02 5.81 13.15
Da12 3.77 3.78 3.81 3.81 3.82 3.8 3.86 3.97 3.99 4.01 3.9 20.01
Da13 3.7 3.7 3.72 3.72 3.79 3.79 3.76 3.86 3.86 3.86 4.86 41.78
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 19. Percentage Improvements for RMSE.
Mwgpr M
ws
gpr Mgpr M
s
gpr Mrf Msvr M
lin
svr Mknn M
s
svr Mwnn Mridge Mnn
De1 2.98 2.93 1.65 1.5 1.6 -0.3 0.38 -2.38 -1.62 -1.75 0.05 -22.06
De2 2.06 2.18 1.22 1.2 0.61 -1.05 -2.65 -2.15 -1.39 -1.95 -0.14 -83.81
De3 4.29 4.15 3.53 3.36 2.55 2.47 2.24 -1.51 -2.31 -2.16 1.59 -12.86
De4 4.05 3.97 3.3 3.2 2.46 2.2 2.0 -1.97 -2.21 -2.52 1.41 -60.39
De5 3.39 3.26 2.53 2.33 2.54 1.56 1.62 -1.45 -2.51 -2.18 1.16 -11.05
De6 4.45 4.24 3.75 3.48 2.74 2.77 2.02 -1.43 -2.04 -2.3 1.46 -15.86
De7 3.39 3.15 2.53 2.27 2.57 1.04 1.62 -1.45 -2.36 -1.6 1.16 -13.0
De8 4.14 4.02 3.3 3.18 2.44 2.88 1.76 -1.73 -2.71 -1.95 0.88 -53.49
De9 0.93 0.89 0.35 0.31 0.24 -2.47 -2.02 -2.95 -2.77 -3.0 -28.94 -61.96
De10 3.11 2.94 2.19 1.99 1.63 0.64 1.23 -2.24 -2.32 -2.89 0.61 -22.57
De11 6.25 6.05 4.81 4.39 4.17 3.43 2.88 -0.26 -1.63 -1.07 2.54 -73.25
De12 2.84 2.67 1.7 1.47 1.39 1.96 1.01 -2.26 -3.31 -2.24 -0.1 -61.66
De13 0.8 0.71 0.61 0.48 -0.98 -1.2 -0.6 -3.09 -3.03 -3.54 -23.2 -6846.22
Da1 2.49 2.49 1.11 1.03 1.18 -1.01 -0.99 -2.54 -3.04 -3.73 -1.1 -51.5
Da2 1.8 1.85 0.64 0.62 0.2 -1.51 -2.44 -2.71 -3.17 -3.79 -1.28 -73.68
Da3 3.67 3.61 2.87 2.75 2.29 1.69 1.1 -1.93 -3.12 -3.26 -2.26 -29.54
Da4 3.49 3.43 2.64 2.53 2.3 1.45 0.82 -2.07 -3.0 -3.12 -6.4 -33.72
Da5 2.72 2.6 1.63 1.46 2.52 0.47 0.13 -1.99 -3.18 -2.93 -2.55 -30.45
Da6 3.83 3.62 3.06 2.78 2.43 1.92 0.88 -1.99 -2.87 -2.94 -1.85 -71.78
Da7 2.72 2.53 1.63 1.39 2.51 -0.07 0.13 -1.99 -3.07 -2.69 -2.55 -29.79
Da8 3.68 3.53 2.87 2.67 2.32 2.28 0.66 -2.11 -3.32 -2.91 -0.26 -134.27
Da9 1.04 1.03 0.17 0.13 -0.27 -2.68 -2.7 -3.23 -2.92 -3.11 -38.13 -102.02
Da10 2.69 2.58 1.77 1.6 1.34 0.25 0.44 -2.44 -3.1 -4.01 -5.4 -47.41
Da11 5.02 4.94 3.51 3.28 3.3 2.1 1.91 -1.91 -2.9 -2.74 -48.79 -236.69
Da12 2.41 2.34 1.52 1.36 1.29 1.61 0.03 -2.6 -3.74 -3.17 -0.91 -417.57
Da13 1.01 0.93 0.51 0.38 -1.48 -1.46 -0.76 -3.39 -3.28 -3.48 -30.03 -1018.57
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 20. Losses Using gRMSE.
Mwgpr M
ws
gpr Msvr Mgpr M
s
gpr Mrf M
lin
svr Mknn Mwnn M
s
svr Mridge Mnn
De1 4.86 4.87 4.96 4.94 4.95 4.93 4.97 5.12 5.14 5.13 5.02 5.88
De2 5.0 4.99 5.09 5.05 5.04 5.07 5.15 5.18 5.22 5.2 5.1 8.62
De3 5.06 5.07 5.07 5.1 5.11 5.16 5.14 5.35 5.44 5.45 5.21 5.72
De4 5.07 5.08 5.09 5.11 5.12 5.16 5.15 5.37 5.46 5.45 5.22 8.68
De5 5.11 5.12 5.12 5.16 5.17 5.15 5.16 5.34 5.45 5.43 5.23 5.62
De6 5.05 5.06 5.06 5.09 5.1 5.15 5.15 5.34 5.44 5.43 5.22 5.92
De7 5.11 5.12 5.14 5.16 5.17 5.16 5.16 5.34 5.41 5.43 5.23 5.78
De8 5.07 5.08 5.07 5.12 5.13 5.16 5.18 5.36 5.42 5.46 5.26 7.28
De9 5.1 5.1 5.17 5.13 5.13 5.11 5.14 5.27 5.33 5.34 6.12 7.35
De10 5.13 5.13 5.17 5.18 5.19 5.21 5.2 5.38 5.47 5.45 5.27 6.1
De11 4.99 5.0 5.05 5.07 5.09 5.09 5.11 5.31 5.38 5.43 5.18 8.06
De12 5.15 5.16 5.13 5.22 5.23 5.23 5.24 5.4 5.45 5.48 5.32 7.63
De13 5.1 5.11 5.11 5.12 5.12 5.17 5.14 5.27 5.36 5.34 5.97 256.36
Da1 5.02 5.02 5.12 5.1 5.1 5.07 5.15 5.26 5.38 5.35 5.2 7.08
Da2 5.12 5.12 5.21 5.19 5.19 5.19 5.26 5.33 5.44 5.42 5.27 7.99
Da3 5.24 5.25 5.26 5.29 5.3 5.32 5.35 5.54 5.67 5.67 5.51 6.55
Da4 5.25 5.26 5.28 5.31 5.31 5.32 5.36 5.54 5.65 5.66 5.65 6.73
Da5 5.3 5.31 5.33 5.36 5.37 5.31 5.39 5.53 5.65 5.64 5.52 6.57
Da6 5.23 5.25 5.25 5.28 5.3 5.31 5.36 5.53 5.64 5.65 5.49 8.14
Da7 5.3 5.31 5.35 5.36 5.38 5.31 5.39 5.53 5.64 5.65 5.52 6.44
Da8 5.25 5.25 5.24 5.3 5.31 5.32 5.38 5.54 5.65 5.67 5.47 10.56
Da9 5.19 5.19 5.28 5.24 5.24 5.24 5.26 5.39 5.43 5.44 6.57 9.26
Da10 5.3 5.31 5.35 5.36 5.37 5.37 5.39 5.56 5.71 5.67 5.63 7.19
Da11 5.17 5.18 5.24 5.26 5.27 5.26 5.28 5.54 5.62 5.65 7.22 14.56
Da12 5.33 5.33 5.3 5.39 5.39 5.38 5.43 5.57 5.66 5.68 5.51 21.96
Da13 5.18 5.19 5.22 5.22 5.22 5.29 5.24 5.39 5.44 5.45 6.31 43.34
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Table 21. Percentage Improvements for gRMSE.
Mwgpr M
ws
gpr Msvr Mgpr M
s
gpr Mrf M
lin
svr Mknn Mwnn M
s
svr Mridge Mnn
De1 2.95 2.88 1.01 1.45 1.32 1.58 0.9 -2.07 -2.49 -2.38 -0.13 -17.3
De2 1.22 1.37 -0.51 0.29 0.31 -0.19 -1.75 -2.4 -3.19 -2.67 -0.86 -70.36
De3 4.33 4.15 4.06 3.54 3.36 2.42 2.75 -1.11 -2.82 -3.12 1.36 -8.25
De4 4.05 3.93 3.7 3.26 3.16 2.33 2.52 -1.51 -3.26 -3.1 1.2 -64.21
De5 3.37 3.2 3.22 2.49 2.26 2.51 2.36 -1.06 -3.05 -2.63 1.1 -6.34
De6 4.52 4.29 4.35 3.8 3.51 2.63 2.62 -1.06 -2.92 -2.71 1.32 -11.89
De7 3.37 3.1 2.83 2.49 2.24 2.49 2.36 -1.06 -2.25 -2.69 1.1 -9.25
De8 4.1 3.98 4.19 3.17 3.08 2.35 2.08 -1.43 -2.56 -3.21 0.49 -37.66
De9 0.23 0.18 -1.16 -0.39 -0.43 0.03 -0.5 -3.07 -4.24 -4.44 -19.8 -43.78
De10 3.05 2.87 2.13 2.08 1.87 1.51 1.6 -1.83 -3.56 -3.19 0.3 -15.42
De11 4.86 4.68 3.67 3.46 3.08 2.91 2.53 -1.12 -2.53 -3.44 1.35 -53.6
De12 2.54 2.4 2.95 1.24 1.03 1.08 0.89 -2.05 -2.98 -3.61 -0.87 -44.25
De13 0.16 0.06 0.02 -0.09 -0.24 -1.12 -0.53 -3.12 -4.81 -4.44 -16.7 -4914.91
Da1 2.7 2.71 0.66 1.15 1.08 1.62 0.01 -2.1 -4.29 -3.75 -0.88 -37.37
Da2 1.27 1.35 -0.52 -0.03 -0.03 -0.12 -1.35 -2.85 -4.83 -4.47 -1.55 -54.15
Da3 3.84 3.76 3.5 2.95 2.82 2.42 1.89 -1.53 -4.02 -3.98 -1.04 -20.19
Da4 3.64 3.56 3.17 2.69 2.56 2.48 1.65 -1.56 -3.62 -3.91 -3.61 -23.41
Da5 2.83 2.69 2.26 1.61 1.42 2.68 1.22 -1.51 -3.63 -3.51 -1.26 -20.54
Da6 4.03 3.8 3.72 3.18 2.86 2.59 1.76 -1.51 -3.42 -3.63 -0.79 -49.27
Da7 2.83 2.61 1.84 1.61 1.34 2.69 1.22 -1.51 -3.41 -3.56 -1.26 -18.21
Da8 3.79 3.65 3.88 2.87 2.68 2.49 1.29 -1.68 -3.66 -3.93 -0.33 -93.6
Da9 0.47 0.45 -1.35 -0.52 -0.55 -0.56 -0.91 -3.38 -4.25 -4.46 -26.04 -77.7
Da10 2.79 2.65 1.92 1.75 1.57 1.45 1.15 -1.95 -4.8 -3.98 -3.21 -31.92
Da11 4.12 4.06 2.88 2.48 2.26 2.57 2.26 -2.6 -4.08 -4.66 -33.8 -169.81
Da12 2.25 2.2 2.89 1.23 1.08 1.34 0.5 -2.23 -3.81 -4.19 -1.23 -302.7
Da13 0.5 0.43 -0.25 -0.09 -0.24 -1.6 -0.58 -3.5 -4.47 -4.61 -21.15 -731.8
See Table 8 for descriptions of the different datasets and Table 9 for descriptions of the models.
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Fig 12. How we Implement Stacking.
A.6 Feature Stacking with models trained on all patients
Up to this point, all the previous learning algorithms described have been trained
specifically on a single patient and then evaluated on new data from that same patient.
To incorporate the available data from the other patients in the dataset, we use stacking
(originally introduced as “stacked generalization” [35]), which involves training higher
levels of learners on a combination of meta-data/data with the predictions of other basic
learners [36]. In our case, this involves training a stacking learner on all the other
patients to produce a stacking model, which is then used to make BG predictions for
each record associated with the current patient. (See Fig 12 for a description of the
stacking process that we use). These BG predictions then become a new feature for the
patient under test.Specifically, we use SVR as our stacking learner and use GPR (resp.,
confidence weighted GPR and SVR) as our base learner, to produce the Msgpr model
(resp., Mwsgpr, M
s
svr). Here the superscript s indicates that the model uses stacking,
whereas the superscript w indicates confidence weighting.
This stacking approach is motivated by the realization that, as our data is
self-reported, some patients (such as patient 16) have a large number of records, while
other patients have relatively few records. Consider the datasets (features and outcome)
for two patients, D1 = {(x1i , y1i )|i = 1..n} and D2 = {(x2j , y2j )|j = 1..m} where m n.
Let f1 : X→ Y and f2 : X→ Y be the true underlying glucose functions for these
patients. Both functions are sufficiently complex that a learning algorithm cannot learn
a good approximation fˆ2 when only learning with D2, but a learning algorithm can
learn a good approximation fˆ1 when only learning with D1. If f1 and f2 are closely
related in some sense – e.g., affinely related f2(x) = a f1(x) + b – then fˆ2 can be learned
using D1 and D2 by first learning fˆ1. As another perspective, we could view this
stacking approach as mimicking health care professionals, who apply the knowledge that
they have acquired from previous patients, to a new patient.
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